Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1

Completed

Conditions: Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IIIA Breast Cancer

Interventions: Drug: ganetespib
Drug: paclitaxel
Biological: trastuzumab
Biological: pertuzumab

First Posted Date: 2014-02-12

Last Posted Date: 2018-06-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT02060253

Locations: 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Phase 2

Completed

Conditions: Isolated Chemotherapy-induced Thrombocytopenia

Interventions: Biological: romiplostim

First Posted Date: 2014-02-03

Last Posted Date: 2024-12-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT02052882

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 3 locations

18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases

Not Applicable

Completed

Conditions: Brain Metastases

Interventions: Procedure: 18F-FCH PET Scan

First Posted Date: 2014-01-16

Last Posted Date: 2022-12-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT02037945

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer

Not Applicable

Completed

Conditions: Localized Stage I-III Esophageal Cancer
Gastroesophageal Junction Cancer

Interventions: Other: nutritional and functional assessments

First Posted Date: 2014-01-06

Last Posted Date: 2022-03-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT02027948

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only), Commack, New York, United States

and more 4 locations

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Not Applicable

Completed

Conditions: Esophagogastric Cancer

Interventions: Radiation: 89Zr-DFO-trastuzumab
Device: PET imaging

First Posted Date: 2013-12-30

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT02023996

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Adenocarcinoma

Interventions: Drug: Regorafenib

First Posted Date: 2013-12-30

Last Posted Date: 2025-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02023333

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

and more 4 locations

Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

Completed

Conditions: Malignant Glioma

Interventions: Behavioral: surveys and cognitive tests

First Posted Date: 2013-12-30

Last Posted Date: 2018-11-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 95

Registration Number: NCT02023346

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, New York, New York, United States

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Phase 2

Active, not recruiting

Conditions: Metastatic Castration Sensitive Prostate Cancer

Interventions: Drug: Degarelix
Drug: Ipilimumab
Procedure: Radical Prostatectomy

First Posted Date: 2013-12-24

Last Posted Date: 2024-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT02020070

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Not Applicable

Completed

Conditions: Non-Small-Cell-Lung Cancer (NSCLC)

Interventions: Drug: 18F-FMISO
Other: PET/CT

First Posted Date: 2013-12-20

Last Posted Date: 2025-04-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT02016872

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Phase 2

Active, not recruiting

Conditions: Rectal Cancer

Interventions: Drug: Oxaliplatin (OXAL)
Drug: 5-Fluorouracil (5-FU)
Drug: Leucovorin
Drug: Capecitabine (Xeloda®)
Radiation: intensity modulated radiotherapy (IMRT)
Behavioral: Quality of Life Questionnaires
Procedure: DRE-Endoscopy

First Posted Date: 2013-12-11

Last Posted Date: 2025-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 358

Registration Number: NCT02008656

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy